Abstract 2438
Background
This study was carried out as descriptive and cross-sectional in order to determine the compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) levels of the nurses working in oncology-hematology and the factors affecting them.
Methods
The sample of the study consisted of 125 oncology-hematology nurses working in two private hospitals, one university hospital. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Descriptive statistics, numbers and percentages and X±SD were used according to the data type. The factors affecting dependent variables were tested with multilevel models (MLM).
Results
In the study, 89.6% (n: 112) of the nurses were women, 80% (n: 100) were unmarried, 70.4% (n: 88) have Bachelor’s degree, mean age was 26.82±5.32, and the average years of total working at oncology was 2.78±2.35, the average weekly working hours was 49.75 ± 4.26, 65.6% (n: 82) said that the social support is not enough. When the mean scores of the nurses were examined, the CF was 13.53±7.25, BO was 20.14±6.77, CS was 37.92±7.40, PS was 32.00±3.44, PR was 135.43±17.29. There was a statistically significant effect of weekly working hour on BO, CS and PS (p < 0.05). 1 hour more work per week leads to a 0.5 point decrease in CS mean scores, 0,45 points increase in BO mean scores and 0,18 points increase in PS mean scores. When we compare the nurses their answers to social support question, nurses who said that social support is insufficient, have 3.1 points higher CF, 2.6 points lower CS, and 8.8 points lower PR mean scores (p < 0.05).
Conclusions
In this study, it was found that nurses had moderate levels of CF, BO and CS. While having social support positively affected the dependent variables, it was found that the increase in the weekly working hours negatively affected. These results are a key finding for the managers of the institutions especially in providing the healthy working life of nurses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract